Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates.

J Antimicrob Chemother

Independent Science, Policy and Regulatory Consultant, Wicklow, Co. Wicklow, Republic of Ireland.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: In recent years, reports have emerged linking the NarAB genes with elevated MICs to non-medically important ionophore coccidiostat class (specifically narasin, salinomycin and maduramycin) and potential co-selection of clinically relevant antibiotic resistance genes in Enterococcus faecalis and Enterococcus faecium.

Methods: We analysed all publicly accessible E. faecalis (n = 7731) and E. faecium (n = 20 594) genomes, focusing specifically on the genomes from broiler-chicken, turkeys, dogs and human clinical infections.

Results: The NarAB gene was more prevalent in broiler isolates (26% E. faecalis, 39.2% E. faecium) compared with human clinical isolates (2.8% E. faecalis, 2.0% E. faecium). In addition, genes associated with resistance to medically important antibiotics of clinical importance for E. faecalis and E. faecium infections were not found in the vicinity of the NarAB gene in isolates from broiler-chicken, and this refutes claims of the presence of co-selection between NarAB and medically important antibiotics. In addition, the pattern of genes near NarAB differed between broiler-chicken and human clinical isolates, as did the genomic sequence types isolated from each species.

Conclusions: These findings indicate that E. faecalis and E. faecium from broiler-chicken are unlikely to contribute resistance genes to human clinical isolates, and this should continue to inform any policy that might limit poultry farmers' and veterinarians' access to ionophore coccidiostats in broiler-chicken.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkaf296DOI Listing

Publication Analysis

Top Keywords

human clinical
20
clinical isolates
12
resistance genes
8
narab gene
8
medically antibiotics
8
faecalis faecium
8
narab
6
clinical
6
isolates
6
faecalis
6

Similar Publications

IGLV3-21-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.

Haematologica

September 2025

Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel.

We previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21R110) for selective targeting of a high-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. Since CLL is a disease of the elderly and a significant fraction of patients is not able to physically tolerate CAR T cell treatment, we explored bispecific antibodies as an alternative for precision targeting of this tumor mutation. Heterodimeric IgG1-based antibodies consisting of a fragment crystallizable region (Fc) attached to both an anti-IGLV3-21R110 Fab and an anti-CD3 (UCHT1) single chain variable fragment (R110-bsAb) selectively killed cell lines engineered to express high levels of the neoepitope as well as primary CLL cells using healthy donor and CLL patient-derived T cells as effectors.

View Article and Find Full Text PDF

Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.

Haematologica

September 2025

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke.

Patient age might influence donor selection priorities in allogeneic hematopoietic stem cell transplantation (allo-HCT), due to the differences in donor age, organ function, and resistance to graft-versus-host disease between younger and older patients. We compared the transplant outcomes among human leukocyte antigen (HLA)-matched related donors (M-RDs, n=4,106), HLA 1-antigen-mismatched related donors (1MM-RDs, n=592), HLA 2-3-antigen-mismatched related donors (23MM-RDs, n=882), HLA-matched unrelated donors (M-UDs, n=3,927), HLA 1-locus-mismatched unrelated donors (1MM-UDs, n=2,474), and unrelated cord blood units (U-CBs, n=5,867) between patients aged.

View Article and Find Full Text PDF

Timing Matters: How Daily Rhythms Affect Remote Ischemic Postconditioning Therapy for Stroke.

Stroke

September 2025

Departments of Radiology and Neurology, Neuroprotection Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston (E.L., R.M.P., K.H., E.H.L., E.E.).

Background: Despite promising preclinical results, remote limb ischemic postconditioning efficacy in human stroke treatment remains unclear, with mixed clinical trial outcomes. A potential reason for translational difficulties could be differences in circadian rhythms between nocturnal rodent models and diurnal humans.

Methods: Male C57BL/6J mice were subjected to transient focal cerebral ischemia and then exposed to remote postconditioning during their active or inactive phase and euthanized at 24 hours and 3 days.

View Article and Find Full Text PDF

Objectives: Acute pyelonephritis (APN) is a common diagnosis among patients presenting to the Emergency Department (ED). It is treated by empiric antibiotics within the ED. With a rise in antimicrobial resistance globally, it is unknown whether patients are being managed with empiric antibiotics that are appropriate for the causative organisms of APN.

View Article and Find Full Text PDF

In-Flight Deterioration Occurs Early in Aeromedical Trauma Patients.

Emerg Med Australas

October 2025

Australian Centre for Health Services Innovation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia.

Reliably defining the risk of adverse in-flight events in aeromedical trauma patients could enable more informed pre-departure treatment and guide central asset allocation to achieve better system-level outcomes. Unfortunately, the current literature base specifically examining the in-flight period is sparse. Flight duration is often considered a proxy for the risk of in-flight deterioration; however, there is limited data to support this commonly held assumption.

View Article and Find Full Text PDF